Hematopoietic stem cell gene therapy for Niemann-Pick disease and other lysosomal storage diseases

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Of the various gene therapy approaches under investigation for the treatment of genetic diseases, hematopoietic stem cell-mediated gene therapy has attracted the most interest. Enriched populations of hematopoietic stem cells can be obtained from diseased individuals, genetically modified to express normal gene products, and then transplanted back into these individuals without the risk of graft versus host disease. Following transplantation and engraftment, hematopoietically-derived cells can repopulate various sites of pathology and express the normal gene product in vivo. Such a procedure has been accomplished in several mouse models of human genetics diseases, leading to partial or complete correction of the disease phenotype, and current efforts are now focused on adapting the success of murine systems to larger animals, including man. This review will focus on the use of hematopoietic stem cell-mediated gene therapy for the treatment of lysosomal storage disorders, and discuss recent data obtained in the laboratory using a murine knock-out mouse model of Types A and B Niemann-Pick disease (NPD). Copyright (C) 1999 Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)179-188
Number of pages10
JournalChemistry and Physics of Lipids
Issue number1-2
StatePublished - Nov 1999


  • Acid sphingomyelinase
  • Gene therapy
  • Hematopoietic stem cells
  • Lysosomal storage diseases
  • Niemann-Pick disease


Dive into the research topics of 'Hematopoietic stem cell gene therapy for Niemann-Pick disease and other lysosomal storage diseases'. Together they form a unique fingerprint.

Cite this